Abiomed's Impella 2.5 enters new US trial
This article was originally published in Clinica
A new clinical trial of Abiomed's Impella 2.5 circulatory support system is set to begin in the US following conditional FDA approval of the study protocol. The Impella device, already approved in Canada and CE marked in the EU, is inserted into the left ventricle in a minimally-invasive procedure, and helps pump blood in heart failure patients.
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.